Esperion Therapeutics
Elena Chekanovsky has a diverse work experience in the pharmaceutical industry. Elena has held various senior director positions at Esperion, including roles in drug product development, supply management and planning, and quality control. Prior to that, they worked as a director at Sio Gene Therapies, where they led CMC projects and managed regulatory dossier information. Elena also has experience at Allergan, where they served as a manager in clinical and CMC planning. Elena started their career at Forest Laboratories, where they held positions as a group leader, project leader, and scientist in research and development. Overall, Elena has a strong background in CMC planning, drug development, and regulatory compliance.
Elena Chekanovsky holds a Master of Science (M.S.) degree in Pharmaceutics/Industrial Pharmacy from Long Island University. Elena also has a Bachelor of Science (B.S.) degree in Biochemistry from Binghamton University. Furthermore, they have obtained a Regulatory Affairs Certificate from RAPS (Regulatory Affairs Certification Program). Additionally, in September 2022, they became a member of RAPS.
This person is not in any teams
This person is not in any offices
Esperion Therapeutics
2 followers
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at ESPERION is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.